Notícias Corvus Pharmaceuticals Inc - CRVS | Ações NASDAQ | ADVFN Brasil

Índice Bovespa

US Dollar vs BRL

As Melhores Corretoras Online

Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.

Cadastre-se

Início
Investir
Ações
EUA
NASDAQ
Corvus Pharmaceuticals Inc (CRVS)
Corvus Pharmaceuticals Inc (CRVS) Notícias

Corvus Pharmaceuticals Inc (CRVS)

5,09

0,39

(8,30%)

Fechado 19 Dezembro 6:00PM

Atrasado por 15 minutos

4,81

-0,28

( -5,50% )

Pré-mercado: 8:10AM

Atrasado por 15 minutos

Capacite seu portfólio: Discussões em tempo real e ideias de negociação acionáveis.

Corvus Pharmaceuticals to Provide Business Update and First Quarter 2024 Financial Results on May 6, 2024

Corvus Pharmaceuticals Announces Pricing of $30.6 Million Registered Direct Offering

Corvus Pharmaceuticals Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2023 Financial Results on March 19, 2024

Form 4 - Statement of changes in beneficial ownership of securities

Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data at the Keystone Symposia on Systemic Autoimmune and Autoinflammatory Diseases

Form 3 - Initial statement of beneficial ownership of securities

Corvus Pharmaceuticals Announces Orphan Drug Designation Granted to Soquelitinib for the Treatment of T Cell Lymphoma

Corvus Pharmaceuticals Appoints Jeffrey Arcara as Chief Business Officer

Form 8-K - Current report

Corvus Pharmaceuticals Announces the Passing of Board Member Edith P. Mitchell

Corvus Pharmaceuticals Presents New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

1
2
3
Próxima

Fóruns

Nenhuma Discussão Encontrada

Criar Nova Discussão

Corvus Pharmaceuticals

Delayed Upgrade Clock

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições